What is the appropriate antibiotic therapy for community-acquired pneumonia?

Antibiotic Therapy for Community-Acquired Pneumonia

For outpatients without comorbidities, use a macrolide (azithromycin or clarithromycin) or doxycycline; for those with comorbidities or recent antibiotic use, use a respiratory fluoroquinolone (levofloxacin 750mg daily or moxifloxacin 400mg daily) OR combine a β-lactam with a macrolide. 1

Outpatient Treatment Algorithm

Previously Healthy, No Risk Factors

• First-line: Macrolide monotherapy (azithromycin 500mg daily or clarithromycin 500mg twice daily) 2, 1
• Alternative: Doxycycline 100mg twice daily 2, 1

With Comorbidities (COPD, diabetes, heart/liver/renal disease, malignancy, immunosuppression)

• Preferred: Respiratory fluoroquinolone monotherapy (levofloxacin 750mg daily, moxifloxacin 400mg daily) 2, 1
• Alternative: High-dose amoxicillin (1g three times daily) or amoxicillin-clavulanate (2g twice daily) PLUS macrolide 2, 1

Critical caveat: If the patient received antibiotics within the past 3 months, select a different antibiotic class to avoid resistance 3, 2, 3. Recent fluoroquinolone use mandates a non-fluoroquinolone regimen, and vice versa.

Hospitalized Patients (Non-ICU)

Use either a respiratory fluoroquinolone alone OR combine a β-lactam with a macrolide—both regimens have equivalent strong evidence. 2, 1

Two Equally Effective Options:

1. β-lactam PLUS macrolide:

   • Ceftriaxone 1-2g daily OR cefotaxime 1-2g every 8 hours OR ampicillin-sulbactam 1.5-3g every 6 hours
   • PLUS azithromycin 500mg daily OR clarithromycin 500mg twice daily 2, 1

2. Respiratory fluoroquinolone monotherapy:

   • Levofloxacin 750mg daily OR moxifloxacin 400mg daily 2, 1

For penicillin allergy: Use respiratory fluoroquinolone alone 2

For contraindications to both macrolides and fluoroquinolones: β-lactam PLUS doxycycline 100mg twice daily 1

ICU Patients (Severe CAP)

Combination therapy is mandatory for severe CAP—use a β-lactam PLUS either azithromycin or a respiratory fluoroquinolone. 2, 1

Standard Severe CAP (No Pseudomonas Risk):

• β-lactam: Ceftriaxone 1-2g daily OR cefotaxime 1-2g every 8 hours OR ampicillin-sulbactam 1.5-3g every 6 hours
• PLUS: Azithromycin 500mg daily OR respiratory fluoroquinolone (levofloxacin 750mg daily or moxifloxacin 400mg daily) 2, 1

The evidence strongly favors β-lactam-macrolide combinations for mortality reduction in severe CAP 4. Multiple observational studies and meta-analyses demonstrate lower mortality with combination therapy versus monotherapy in ICU patients.

Pseudomonas Risk Factors Present:

Risk factors include: severe structural lung disease (bronchiectasis, cystic fibrosis), recent hospitalization, recent antibiotics, or ICU stay 3, 2, 3

Use antipseudomonal β-lactam:

• Piperacillin-tazobactam 4.5g every 6 hours OR cefepime 2g every 8 hours OR imipenem 500mg every 6 hours OR meropenem 1g every 8 hours
• PLUS: Ciprofloxacin 400mg IV every 8 hours OR levofloxacin 750mg daily
• OR: Antipseudomonal β-lactam PLUS aminoglycoside (gentamicin 5-7mg/kg daily or tobramycin 5-7mg/kg daily) PLUS azithromycin or respiratory fluoroquinolone 3, 2

MRSA Risk Factors Present:

Risk factors include: prior IV antibiotics within 90 days, hospitalization in unit where >20% of S. aureus is MRSA, prior MRSA colonization 5

Add MRSA coverage:

• Vancomycin 15mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600mg IV every 12 hours 2, 5

Duration of Therapy

The 2025 guidelines represent a paradigm shift toward shorter, personalized antibiotic courses based on clinical stability. 6, 7, 8

Clinical Stability Criteria:

• Temperature ≤37.8°C
• Heart rate ≤100 beats/min
• Respiratory rate ≤24 breaths/min
• Systolic BP ≥90 mmHg
• Oxygen saturation ≥90% on room air
• Able to take oral medications 2

Duration Recommendations:

• Non-severe CAP stabilized by day 3: 3 days of antibiotics 6, 7, 8
• Moderate CAP stabilized by day 5: 5 days of antibiotics 6, 7, 8
• Severe CAP or ICU patients: Minimum 5 days, continue until clinical stability achieved 7, 8
• Complicated pneumonia (empyema, abscess): Prolonged duration required 6, 7

This represents a significant departure from the previous 7-10 day standard. Multiple RCTs and meta-analyses confirm non-inferiority of 3-7 day courses versus longer treatment 6.

Key Clinical Pitfalls

Macrolide resistance: In regions where >25% of S. pneumoniae shows high-level macrolide resistance (MIC ≥16 mg/mL), avoid macrolide monotherapy even in previously healthy patients—use alternatives from recommendation 16 2

Recent antibiotic exposure: This is the single most important risk factor for drug-resistant S. pneumoniae. Always ask about antibiotics in the past 90 days and switch antibiotic classes 3, 2, 3

Switch to oral therapy: Transition from IV to oral antibiotics once hemodynamically stable, clinically improving, and able to take oral medications—do not delay discharge for observation on oral therapy 2

First dose timing: For ED admissions, administer the first antibiotic dose while still in the ED, not after reaching the floor 2

Viral testing caveat: The 2025 guidelines suggest withholding antibiotics in otherwise healthy outpatients with positive viral testing and no infiltrate on imaging, though this remains controversial and requires careful clinical judgment 7, 8